Give it time, there are a lot of court cases pending yet, but as the wins mount up we should gain traction and hopefully recover towards 1800 again..
Happy to hold and build HLN too, another keep for life share as their debt comes off and dividends ramp up.. :o) |
So predictable these MM,s. You could not make it up. |
Bizarre how this share reacts to news |
It feels like ex dividend was today |
Love the market reaction. Zantac is blamed for the laggard share price here all the time but any positive news on that front and the opening bell is always red! |
Down a tad at the open. |
Good news for Gsk. Should open at 1700.
Let's see how market reacts. |
Interesting choice of words in the RNS...Court's ruling is consistent with scientific consensus that there is no consistent or reliable evidence that ranitidine increases the risk of *ANY* cancer |
As these Zantac court case wins stack up it adds more and more weight to the appeals underway in Delaware..We soon recovered most of the XD drop too..Onward and upward, see if we can recover to 1800 again.. |
I hope we're in for a very good opening this morning! |
hTTps://www.londonstockexchange.com/news-article/GSK/statement-zantac-ranitidine-litigation/16621656 |
Yup, that's what I'll probably do |
Averaging up? |
Was hoping for a larger drop to add one final tranche but never mind. My average in price is 1510p over the last couple of weeks |
Great open bearing in mind ex div |
Minus 15 pence on the open, but GSK should recover most of it by the closing bell.. :o) |
Not always does a share price drop ('big' or otherwise) on x-div day. Even if it does, it more often regains the amount the same day or soon after. |
So big drop tomorrow then . |
x-div tomorrow .... ;0) |
1500-1600 took a month to cover, a way to go to get back to the April highs of 1800 before the Zantac press coverage and court case results came to light..
Good progress.. :o) |
 JO Hambro actively managing GSKLegal headwinds have battered GSK (GSK) and JOHCM manager Mark Costar is managing his position 'proactively' as the case takes new twists and turns.The Citywire Elite Companies AAA-rated pharmaceutical giant is the second-largest holding in Costar's JOHCM UK Dynamic fund, where it makes up 4.8% of the £502m portfolio.GSK has been battling legal litigation over its heartburn drug Zantac's links to cancer but Costar said he took the view that the legal battle and associated liabilities 'were already more than discounted in the price, masking an improving R&D productivity story and a broadening pipeline of attractive therapeutic assets'.However, the latest legal update saw a Delaware court reverse its decision on the key Daubert case which 'renewed uncertainty' and Costar said his original view 'at least in the short term... has proven to be misplaced'.'Despite strong first quarter results lending clear credence to the core fundamental story, and whilst an appeal has already begun and previous precedents lean heavily in favour of the equity at this juncture, we are not naïve enough to believe recovery can happen in the absence of this being resolved,' he said.'The shares are clearly very cheap, and the underlying progress is tangible, but we will manage the position size proactively in this period.'The shares gained 1.3% to £15.93 on Tuesday. |
GSK's upcoming ex-dividend date is Aug 15, 2024. Shareholders who own GSK stock before this date will receive the next dividend payment of 15p per share on Oct 10, 2024 |
That's not new news though |
Not to scare you but there are about 79k on the Delaware docket :/ |
Register for streaming realtime charts, analysis tools, and prices.
Hot Features
Premium
